Before, during, and/or after pregnancy regardless of lactation status, one softgel daily or as directed by a licensed healthcare practitioner. Supplement Facts Serving Size: 1 Softgel Amount Per Serving % Daily Value for Pregnant & Lactating Women Vitamin C (as ascorbic acid) 100 mg 167% Vitamin D (Vitamin D 3 as cholecalciferol) 400 IU 100% Vitamin E (as d-alpha tocopherol) 30 IU 100% Thiamin (as thiamine mononit...
Prenatal/Postnatal Prescription Dietary Supplement
69543-370-30
Rx
Virt-Nate DHA is an orally administered prenatal/postnatal prescription dietary supplement with DHA and should be administered under the supervision of a licensed medical practitioner.
Before, during, and/or after pregnancy regardless of lactation status, one softgel daily or as directed by a licensed healthcare practitioner.
| Supplement Facts | ||
|---|---|---|
| Serving Size: 1 Softgel | ||
| Amount Per Serving | % Daily Value for Pregnant & Lactating Women | |
| Vitamin C (as ascorbic acid) | 100 mg | 167% |
| Vitamin D (Vitamin D3 as cholecalciferol) | 400 IU | 100% |
| Vitamin E (as d-alpha tocopherol) | 30 IU | 100% |
| Thiamin (as thiamine mononitrate) | 3 mg | 176% |
| Riboflavin | 3 mg | 150% |
| Vitamin B6 (as pyridoxine HCl) | 20 mg | 800% |
| Folic Acid | 1 mg | 125% |
| Vitamin B12 (as cyanocobalamin) | 15 mcg | 188% |
| Iron (as ferrous fumarate) | 28 mg | 156% |
| Magnesium (as magnesium oxide) | 30 mg | 7% |
| Zinc (as zinc oxide) | 20 mg | 133% |
| Copper (as cupric sulfate) | 1 mg | 50% |
| Omega-3 Fatty Acids (DHA-EPA) | 200 mg | * |
* Daily Value not established
Other Ingredients: Gelatin, Glycerin, Soybean Oil, Beeswax, Purified Water, Soy Lecithin, Natural Creamy Orange Flavor, Annatto Powder, Titanium Dioxide, and Ethyl Vanillin. Contains Fish Oil and Soy.
KEEP THIS OUT OF REACH OF CHILDREN
Virt-Nate DHA should not be used by patients with known history of hypersensitivity to any of its ingredients.
| WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. KEEP THIS PRODUCT OUT OF REACH OF CHILDREN. In case of accidental overdose, call a doctor or poison control center immediately. |
High levels of folic acid may, especially in older adults, hide signs of Vitamin B-12 deficiency (such as pernicious anemia, a condition that can cause nerve damage).
Concurrent use of folic acid has been associated with enhanced phenytoin metabolism, lowering the level of the AED in the blood and allowing breakthrough seizures to occur. Caution should be used when prescribing this product among patients who are receiving treatment with phenytoin or other anticonvulsants.
Exercise caution with the concomitant use of folinic acid and trimethoprim-sulfamethoxazole for the acute treatment of Pneumocystis carinii pneumonia in patients with HIV infection as it is associated with increased rates of treatment failure and mortality in a placebo controlled study.
The action of levodopa is antagonized by pyridoxine.
Products containing iron should not be used during dimercaprol therapy. Dimercaprol can bind to iron and cause kidney damage.
Avoid administering omega-3 fatty acids to patients with inherited or acquired predisposition toward bleeding, including patients taking anticoagulants. Exercise caution with these patients to ensure that the prescribed dosage of DHA does not exceed 1 gram (1000 mg) per day.
Allergic sensitization has been reported following oral administration of folic acid.
Iron can cause mild gastrointestinal side effects, particularly when taken on an empty stomach.
Concurrent use of folic acid has been associated with enhanced phenytoin metabolism, lowering the level of the AED in the blood and allowing breakthrough seizures to occur.
Folinic acid may enhance the toxicity of fluorouracil.
High levels of folic acid may result in decreased serum levels of pyrimethamine.
Concurrent administration of chloramphenicol and folinic acid in folate-deficient patients may result in antagonism of the hematopoietic response to folate.
Antiepileptic drugs (including, but not limited to, phenytoin, carbamazepine, primidone, valproic acid, fosphenytoin, valproate, phenobarbital and lamotrigine) have been shown to impair folate absorption and increase the metabolism of circulating folate.
Fluoxetine exerts a noncompetitive inhibition of the 5-methyltetrahydrofolate active transport system in the intestine.
Decreased folic acid levels have been reported to be associated with the administration of Cholestyramine, Colestipol, Cycloserine, Dihydrofolate Reductase Inhibitors (aminopterin, methotrexate, pyrimethamine, triamterene, and trimethoprim), L-dopa, colchicine, oral contraceptives, methylprednisolone, pancreatic extracts (pancreatin, pancrelipase), prolonged intravenous pentamidine, smoking and alcohol consumption, sulfasalazine, metformin, heme iron, isotretinoin, and after a 6-month course of therapy, warfarin can produce a significant impairment of folate status.
Furosemide, a loop diuretic, can decrease thiamin levels.
There have been case reports that fluorouracil may increase thiamin metabolism.
Vitamin B6 should not be given to patients receiving the drug levodopa because the action of levodopa is antagonized by Vitamin B6. However, Vitamin B6 may be used concurrently in patients receiving a preparation containing both carbidopa and levodopa.
Isoniazid can produce a Vitamin B6 deficiency.
Antibiotics, cholestyramine, colchicine, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12, and nitrous oxide can produce a functional vitamin B12 deficiency.
Some thiazide diuretics, such as hydrochlorothiazide, as well as antacids, bile acid sequestrants (such as cholestyramine), mineral oil, orlistat, olestra, cimetidine, and anticonvulsant medications may reduce the absorption or increase the catabolism of Vitamin D.
Vitamin D supplementation should not be given with calcium to patients with hypercalcemia or conditions that may lead to hypercalcemia such as hyperparathyroidism or those who form calcium-containing kidney stones.
Iron supplements might reduce the amounts of levodopa available to the body and diminish its clinical effectiveness.
Levothyroxine ingested simultaneously with iron can result in clinically significant reductions in levothyroxine efficacy.
Proton pump inhibitors reduce the acidity of stomach contents and can reduce iron absorption.
Zinc may decrease absorption of quinolone or tetracycline antibiotics.
Concomitant use of penicillamine and copper can cause decreased absorption of both substances.
Ingestion of more than 3 grams per day of omega-3 fatty acids (ALA, EPA, and DHA) may have potential antithrombotic effects, and may increase bleeding times.
Avoid administering omega-3 fatty acids to patients with inherited or acquired predisposition toward bleeding, including patients taking anticoagulants. Exercise caution with these patients to ensure that the prescribed dosage of DHA does not exceed 1 gram (1000 mg) per day.
Virt-Nate DHA is a prescription folate dietary supplement formulated for use before, during and/or after pregnancy regardless of lactation status.
KEEP THIS PRODUCT OUT OF REACH OF CHILDREN.
Adequate folate in healthful diets may reduce a woman's risk of having a child with a brain or spinal cord defect.
Virt-Nate DHA is supplied as annatto colored softgel, imprinted with "V370," dispensed in bottles of 30 softgels.
Store at controlled room temperature 15° to 30°C (59° to 86°F).
Protect from light and moisture. Dispense in a tight, light-resistant container.
Call your licensed medical practitioner about side effects. You may report side effects by calling Virtus at 1-888-848-3593 or FDA at 1-800-FDA-1088.
KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN
Rx
Manufactured for
Virtus Pharmaceuticals, LLC
Tampa, FL 33619
1-888-848-3593
Made in Canada
Rev. 12/2015
VIRTUS
PHARMACEUTICALS
69543-370-30
Virt-Nate DHA
PRENATAL/POSTNATAL
Prescription Dietary Supplement
with DHA
Rx
30 Softgels
Made in Canada
| Class | Version | Type | Effective |
|---|---|---|---|
| ASCORBIC ACID Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| CHOLECALCIFEROL Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| CYANOCOBALAMIN Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| MAGNESIUM CATION Pharmacologic Class Indexing | 4 | Indexing - Pharmacologic Class | 20180813 |
| OMEGA-3 FATTY ACIDS Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| PYRIDOXINE Pharmacologic Class Indexing | 1 | Indexing - Pharmacologic Class | 20170310 |
| ZINC CATION Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 69543-370-30 | Virt-Nate DHA | 30 in 1 BOTTLE | CAPSULE | 30 | 1 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 69543-370 | VIRT-NATE DHA (ASCORBIC ACID, CHOLECALCIFEROL, .ALPHA.-TOCOPHEROL, D-, THIAMINE MONONITRATE, RIBOFLAVIN, PYRIDOXINE HYDROCHLORIDE, FOLIC ACID, CYANOCOBALAMIN, FERROUS FUMARATE, MAGNESIUM OXIDE, ZINC OXIDE, CUPRIC SULFATE, AND OMEGA-3 FATTY ACIDS) CAPSULE [VIRTUS PHARMACEUTICALS] | 1 | 1 package rows | 20160123_e554e0db-5f15-46d4-be02-dba3ba845063.zip |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 69543-370-30 | EA - Each | 69543-370 | ca1cf7d2-e5f7-493f-889e-8ec19e696b28 | 1 | 2016-02-04 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 69543-370 | 69543-370-30 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| ASCORBIC ACID | PQ6CK8PD0R | ACTIB |
| CHOLECALCIFEROL | 1C6V77QF41 | ACTIB |
| .ALPHA.-TOCOPHEROL, D- | N9PR3490H9 | ACTIB |
| THIAMINE MONONITRATE | 8K0I04919X | ACTIR |
| RIBOFLAVIN | TLM2976OFR | ACTIB |
| PYRIDOXINE HYDROCHLORIDE | 68Y4CF58BV | ACTIM |
| FOLIC ACID | 935E97BOY8 | ACTIB |
| CYANOCOBALAMIN | P6YC3EG204 | ACTIB |
| FERROUS FUMARATE | R5L488RY0Q | ACTIM |
| MAGNESIUM OXIDE | 3A3U0GI71G | ACTIM |
| ZINC OXIDE | SOI2LOH54Z | ACTIM |
| CUPRIC SULFATE | LRX7AJ16DT | ACTIM |
| OMEGA-3 FATTY ACIDS | 71M78END5S | ACTIB |
| GELATIN | 2G86QN327L | IACT |
| GLYCERIN | PDC6A3C0OX | IACT |
| SOYBEAN OIL | 241ATL177A | IACT |
| YELLOW WAX | 2ZA36H0S2V | IACT |
| WATER | 059QF0KO0R | IACT |
| LECITHIN, SOYBEAN | 1DI56QDM62 | IACT |
| TITANIUM DIOXIDE | 15FIX9V2JP | IACT |
| ETHYL VANILLIN | YC9ST449YJ | IACT |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Ascorbic Acid | ASCORBIC ACID | Renova Pharmaceuticals LLC | a6481bae-2397-44c7-a51d-4f47ad91bd2c | 2026-08-19 | Warnings, Adverse reactions | ASCORBIC ACID |
| Ascor | ASCORBIC ACID | McGuff Pharmaceuticals, Inc. | 388aad52-fc01-4784-9791-1dbc80c69306 | 2026-05-29 | Warnings, Adverse reactions | ASCORBIC ACID |
| Ascorbic Acid | ASCORBIC ACID | Fresenius Kabi USA, LLC | 1606e29f-0e80-4069-b688-daab9cbff20a | 2025-12-17 | Warnings, Adverse reactions | ASCORBIC ACID |
| Skin Renewing Serum | ASCORBIC ACID | Guangzhou Danting Bath&Body Care Industry Co. Ltd | 396c2a8d-ac95-cbef-e063-6294a90aff39 | 2025-08-23 | Warnings | ASCORBIC ACID |
Adverse event summaries are temporarily unavailable. Other product information remains available.